BUHLMANN Kinase Inhibition Assay Citations Archives -Flow CAST BAT

Category: BÜHLMANN Kinase Inhibition Assays Citations

Flow CAST® is for Research Use Only. Not for use in diagnostic procedures in the US and Canada. The citation list should be used for information only.

Development of a Robust Automated 384-well Whole Blood Flow Cytometry Assay

Flow CAST®Kinase Inhibition Assay Citation: Wise S. et al. Development of a Robust Automated 384-well Whole Blood Flow Cytometry Assay. SLAS 2014. 3rd Annual Conference & Exhibition. January 18-22, 2014. San Diego, CA Highlights from this Poster "Monitoring basophil activation in whole blood via flow cytometry is an accurate method for measuring a pharmacodynamic response
Continue Reading

Discovery of PI3K Delta Inhibitors for the Treatment of Inflammatory and Autoimmune Disease

Flow CAST® – Kinase Inhibition Assay Citation: Matthews, D.J. et al. Discovery of PI3K delta inhibitors for the treatment of inflammatory and autoimmune disease. 2012 New York Academy of Sciences Meeting Poster.  "Importantly, PWT143 inhibits basophil activation (as measured by surface CD63 expression in a whole blood assay) with subnanomolar potency in response to anti-IgE stimulation
Continue Reading

TGR-1202 Suppresses Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Cells via Selective Inhibition of PI3Kδ Kinase

Flow CAST® – Kinase Inhibition Assay Citation: VakkalankaS. et al. TGR-1202 suppresses acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cells via selective inhibition of PI3Kδ kinase. 2012 ASH Meeting Poster. "TGR-1202 demonstrated significant potency against PI3Kδ (22.2 nM) with several fold selectivity over the α (>10000), β (>50), and γ (>48) isoforms. Additionally, the
Continue Reading

Brutontyrosine Kinase Inhibitor Ibrutinib(PCI-32765) has Significant Activity in Patients with Relapsed/Refractory B-cell Malignancies

Flow CAST® – Kinase Inhibition Assay Citation: Advani, R.H. et al. Brutontyrosine kinase inhibitor ibrutinib(PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J ClinOncol. 2013 Jan 1; 31(1): 88-94. PMID: 23045577 "A decrease in anti–IgE-stimulated basophil degranulation was observed, consistent with the role of BTK downstream of the high-affinity IgE receptor."
Continue Reading

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

Flow CAST® – Kinase Inhibtion Assay Citation: Winkler, DG et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. doi: 10.1016/j.chembiol.2013.09.017. Epub 2013 Nov 7. PMID: 24211136. "These studies demonstrate that IPI-145 exerts profound effects on adaptive and innate immunity by inhibiting
Continue Reading

CAL-101, A p110delta Selective Phosphatidylinositol-3-Kinase Inhibitor for the Treatment of B-cell Malignancies, Inhibits PI3K Signaling and Cellular Viability

Flow CAST® - Kinase Inhibition Assay Citation: Lannutti, B.J. et al. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011 Jan 13; 117(2): 591-594. PMID: 20959606. "We have thus described the biochemical and cellular activity of CAL-101, a selective and potent inhibitor of p110δ; such targeted
Continue Reading